CD274 and non-small cell lung carcinoma: The co-administration of probiotics can modulate the gut microbiota, thereby enhancing the efficacy of PD-1/PD-L1 inhibitors and boosting the function of immune cells within the gut, significantly prolonging the survival of NSCLC patients (90).